Compare Johnson & Johnson (JNJ) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Ferrari NV — how do they compare? Johnson & Johnson trades at $261.43 (market cap $618.09B), while Ferrari NV trades at $389.91 (market cap $67.35B). The key difference: Johnson & Johnson is far larger — about 9.2× Ferrari NV's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Ferrari NV for 126 Days on average.
| JNJ | RACE | |
|---|---|---|
Market Cap | $618.09B | $67.35B |
Volume | 6,050,983 | 390,618 |
Sector | Health | Consumer Cyclical |
52-Week High | $278.43 | $436.54 |
52-Week Low | $186.00 | $314.63 |
Typical Hold Time | 129 Days | 126 Days |
Enterprise Value | $646.37B | $69.22B |
Dividend Yield | 2.09% | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Ferrari (RACE) trades at $389.91, up 0.91% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue and net income have grown steadily, reaching $7.15B and $1.60B in 2025, respectively. The company maintains high profitability margins and a robust balance sheet, though cash flow trends show recent volatility. Recent news highlights a share buyback program and strategic partnerships, supporting investor confidence.
The outlook for Ferrari remains positive due to consistent earnings beats, high margins, and analyst optimism, with a consensus price target of $462.75 implying 18.7% upside. Risks include valuation multiples above industry averages, competitive pressures in the luxury automotive sector, and macroeconomic sensitivity. Institutional buying activity and a dominant buy rating from analysts underscore long-term growth potential, but investors should monitor execution on future earnings and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
